RAHWAY, N.J., Sept. 26, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it has donated more than seven million NOBIVAC® rabies vaccines through the Company’s Afya Program, since it was founded. “Communities experiencing ongoing […]
RAHWAY, N.J., September 12, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced new data demonstrating the safety and efficacy of NUMELVI® (atinvicitinib) Tablets for Dogs and MOMETAMAX ULTRA® (gentamicin, posaconazole, and mometasone furoate […]
NUMELVI from Merck Animal Health is the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J., July 24, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United […]
RAHWAY, N.J., June 12, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the NOBIVAC® L6 and NOBIVAC® […]
If Approved, NUMELVI Will Be the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J., June 12, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States […]
RAHWAY, NJ, May 16, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the INNOVAX®-ND-IBD-ILT vaccine. […]
New vaccine reduces viraemia and clinical signs of disease caused by avian reovirus, expanding NOBILIS MULTRIVA portfolio RAHWAY, N.J., March 27, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced that the European Commission has […]
The new formulation targets internal and external parasites, expanding the BRAVECTO® portfolio RAHWAY, N.J., November 26, 2024 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Commission has granted the marketing authorization for […]
Vaccine can now be administered intramuscularly or through subcutaneous injection as well as at the same time as BOVILIS® CRYPTIUM® Subcutaneous injections are generally well-tolerated by animals, can minimize pain and distress, and improve meat quality[i] RAHWAY, N.J., October 15, 2024 – Merck Animal Health, known as MSD Animal Health outside of the United States […]
RAHWAY, N.J., March 14, 2024 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the NOBILIS MULTRIVA™ RT+IBm+ND+Gm+REOm+EDS vaccine to […]